Screening for Ovarian Cancer

被引:34
作者
Cragun, Janiel Marie [1 ]
机构
[1] Univ Arizona, Dept Obstet & Gynecol, Tucson, AZ 85724 USA
关键词
HIGH-RISK; TRANSVAGINAL ULTRASOUND; MUTATION CARRIERS; FAMILY-HISTORY; TUMOR-MARKERS; CA125; WOMEN; SERUM; PROTEOMICS; SURVEILLANCE;
D O I
10.1177/107327481101800103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ovarian cancer remains the most deadly of the gynecologic cancers. It is difficult to diagnose until in advanced stages. An effective screening test may help to decrease mortality from ovarian cancer. Due to the low incidence of ovarian cancer in the general population, a good screening test must have high sensitivity and specificity to allow accurate detection without excessive false-positive results. Thus, effective screening for ovarian cancer has remained elusive. Methods: Studies evaluating screening methods for ovarian cancer are reviewed. Screening methods investigated include ultrasound, CA-125, and serum proteins. Results: The use of CA-125 or ultrasound alone does not result in adequate sensitivity or specificity for routine screening. A combination of the two modalities improves sensitivity, specificity, and positive predictive value. Using a combination of serum proteins may also improve sensitivity, specificity, and positive predictive value, but such studies have yet to be validated. Conclusions: No effective screening methods for ovarian cancer that have been adequately validated are available. Routine screening for ovarian cancer in the general population is not currently recommended.
引用
收藏
页码:16 / 21
页数:6
相关论文
共 47 条
  • [1] Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO
  • [2] 2-L
  • [3] American Cancer Society, 2009, IS OV CANC STAG
  • [4] Combining a symptoms index with CA 125 to improve detection of ovarian cancer
    Andersen, M. Robyn
    Goff, Barbara A.
    Lowe, Kimberly A.
    Scholler, Nathalie
    Bergan, Lindsay
    Dresher, Charles W.
    Paley, Pamela
    Urban, Nicole
    [J]. CANCER, 2008, 113 (03) : 484 - 489
  • [5] Use of a symptom index, CA125 and HE4 to predict ovarian cancer
    Goff, B.
    Andersen, M.
    Lowe, K.
    Scholler, N.
    Bergan, L.
    Drescher, C.
    Paley, P.
    Urban, N.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S103 - S103
  • [6] [Anonymous], AHRQ PUBLICATION
  • [7] [Anonymous], FDA CLEARS TEST OV C
  • [8] [Anonymous], 2010, Cancer Facts Figures 2010
  • [9] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [10] Early detection of ovarian cancer
    Badgwell, Donna
    Bast, Robert C., Jr.
    [J]. DISEASE MARKERS, 2007, 23 (5-6) : 397 - 410